Radiopharm Theranostics Ltd (ASX:RAD) has reached an agreement with Australia's Nuclear Science and Technology Organisation (ANSTO) for the supply of isotope non-carrier-added lutetium-177 (Lu-177) for the company’s trials in Australia.
Shipment of the isotope begins next month and will be used in combination with Radiopharm’s propriety nanobody in a Phase I therapeutic dose escalation trial in patients with non-small cell lung cancer.
The trial is planned to start in the first quarter of next year in collaboration with GenesisCare and ANSTO.
Revolutionising cancer treatment
“ANSTO is committed to work that improves human health and saves lives through technologies for diagnostic, therapeutic and innovative treatments for current and emerging diseases,” said ANSTO chief executive officer Shaun Jenkinson.
“We are excited that the isotopes we will supply to Radiopharm Theranostics will go toward expanding this vision at it seeks to revolutionise cancer treatment.”
Radiopharm Theranostics’ CEO and managing director Riccardo Canevari added: “ANSTO is one of Australia’s largest public research organisations and is widely recognised as an international leader in the field of nuclear science and technology.
“Partnering with ANSTO for the supply of lutetium-177 is an important step as we move forward on our trials in Australia.”
Treating oncological diseases
Radiopharm Theranostics is a clinical-stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need.
The company listed late last year and has a pipeline of four distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer.